M. Leung

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

K. Davis, S. Rives, Krysta D Schlis, 2018, The New England journal of medicine.

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

S. Grupp, D. Porter, B. Levine, 2014 .

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

S. Rives, Krysta D Schlis, A. Baruchel, 2021, Journal for ImmunoTherapy of Cancer.

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

S. Grupp, B. Levine, C. June, 2019, CPT: pharmacometrics & systems pharmacology.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

S. Grupp, B. Levine, C. June, 2018, Clinical Cancer Research.

CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

S. Grupp, B. Levine, C. June, 2017 .

Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.

E. Calleja, S. Mulgaonkar, M. Pescovitz, 2007, British journal of clinical pharmacology.

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

K. Davis, S. Rives, A. Baruchel, 2018, Blood.

Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine

P. Rosenthal, S. Lobritto, M. Leung, 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015, Journal of Cancer Research and Clinical Oncology.

Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

D. Lebwohl, T. Taran, M. Leung, 2019, Current Hematologic Malignancy Reports.

PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

P. Riedell, U. Jaeger, M. Leung, 2019, Hematological Oncology.

Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial

K. Davis, S. Rives, A. Baruchel, 2019, Biology of Blood and Marrow Transplantation.

Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019

S. Rives, S. Grupp, Birgit Jaitner, 2017 .